ChAdOx1 MERS

BIOLOGICAL2 trials

Sponsors

University of Oxford, King Abdullah International Medical Research Center

Conditions

MERS (Middle East Respiratory Syndrome)Middle East Respiratory Syndrome Coronavirus

Phase 1

Safety and Immunogenicity of a Candidate MERS-CoV Vaccine (MERS001)

TerminatedNCT03399578

University of OxfordMERS (Middle East Respiratory Syndrome)

Start: 2018-03-14End: 2021-09-17Updated: 2021-10-20

A Clinical Trial to Determine the Safety and Immunogenicity of Healthy Candidate MERS-CoV Vaccine (MERS002)

CompletedNCT04170829

King Abdullah International Medical Research CenterMiddle East Respiratory Syndrome Coronavirus

Start: 2019-12-17End: 2020-11-26Updated: 2020-12-01

Related Papers

Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial.

2021-11-0340 citations

A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial

Nature Communications2021-07-3057 citations

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.

2020-04-21168 citations